<SEC-DOCUMENT>0001171843-23-002299.txt : 20230414
<SEC-HEADER>0001171843-23-002299.hdr.sgml : 20230414
<ACCEPTANCE-DATETIME>20230414070006
ACCESSION NUMBER:		0001171843-23-002299
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230413
FILED AS OF DATE:		20230414
DATE AS OF CHANGE:		20230414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		23819689

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_041323.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES </B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Date of report: April 13, 2023</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Commission File Number: 001-38844</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 24pt; text-align: center; margin: 0pt 0"><B>GENFIT S.A. </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>(Translation of registrant&#8217;s name into English) </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>59120 Loos, France</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Address of principal executive office)</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&#9746; Form 20-F &#9;&#9744; Form 40-F</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXHIBIT LIST</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%">
    <P STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit</B></P></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">
    <P STYLE="border-bottom: black 1pt solid; font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Description</B></P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-size: 10pt">Press Release dated April 13, 2023.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SIGNATURES</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 48%"><FONT STYLE="font-size: 10pt">Date: April 13, 2023</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; width: 43%"><FONT STYLE="font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #005478"><B>GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate
Update</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #005478">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt">&bull;</TD><TD STYLE="padding-right: 70.6pt"><B>Cash, cash equivalents and current
                                            financial assets totaled &euro;140.2 million<FONT STYLE="font-size: 9pt"><SUP>1</SUP></FONT>
                                            as of December 31, 2022, expected to fund operations through third quarter 2024</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="padding-right: 70.75pt"><B>Transformative milestone expected towards end of second quarter 2023, with topline data readout
for Phase 3 ELATIVE&reg; evaluating elafibranor in primary biliary cholangitis (PBC)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD><B>Multiple events in second quarter 2023:</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #56879F"><TR STYLE="vertical-align: top">
<TD STYLE="width: 67.75pt"></TD><TD STYLE="width: 21.25pt">&ndash;</TD><TD><B>1st patient screening in a Phase 2 study evaluating VS-01 in acute on-chronic liver failure (ACLF)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #56879F"><TR STYLE="vertical-align: top">
<TD STYLE="width: 67.7pt"></TD><TD STYLE="width: 21.3pt">&ndash;</TD><TD><B>1st patient screening in a Phase 1b/2 evaluating GNS561 in cholangiocarcinoma (CCA)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #56879F"><TR STYLE="vertical-align: top">
<TD STYLE="width: 67.75pt"></TD><TD STYLE="width: 21.25pt">&ndash;</TD><TD STYLE="padding-right: 70.6pt"><B>Phase 1 data for NTZ in ACLF, for 2 studies in hepatic impaired and renal impaired patients (Phase
2 study initiation targeted for the second half of 2023)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt">&bull;</TD><TD STYLE="padding-right: 70.65pt"><B>Successful acquisition of Versantis AG at end of 2022 strengthens GENFIT&rsquo;s pipeline that now
includes 4 clinical-stage programs and 2 preclinical-stage programs</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18.05pt">&bull;</TD><TD><B>Conference call (English and French) on April 14, 2023 at 8am ET / 1pm GMT / 2pm CET</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 70.1pt 0pt 25.15pt"><FONT STYLE="color: #005478"><B>Lille (France); Cambridge (Massachusetts, United
States); Zurich (Switzerland); April 13, 2023 - GENFIT (Nasdaq and Euronext: GNFT)</B></FONT><FONT STYLE="color: #232323">, a late-stage
biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet
medical needs, today announced annual financial results for the year ended December 31, 2022. A summary of the consolidated financial
statements is included further below.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 70.1pt 0pt 25.15pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><B>Pascal Prigent, CEO of GENFIT, commented</B>:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 53.5pt; color: #232323"><I>&ldquo;2022 was a transformative year
for GENFIT. It was marked by both the fast progression of our lead program and the expansion of our pipeline in rare and severe liver
diseases, notably with the acquisition of Versantis AG. We are now approaching an inflection point: this quarter we expect to report data
from our pivotal Phase 3 study in PBC. There is still an important unmet medical need in this market, and we are very encouraged by the
previous Phase 2 data reported as part of this program. We believe elafibranor has significant potential, and we hope it will be demonstrated
soon. Beyond this exciting milestone, we have built a rich pipeline, that now includes 3 additional phase 2-stage programs and 2 preclinical-stage
programs. This pipeline, combined with a robust cash position and the near-term commercial perspectives for elafibranor, provide us with
a unique opportunity to drive transformative value in 2023.&rdquo;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 53.5pt; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt">I.</TD><TD>2022 Key Highlights</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 25.15pt; color: #56879F"><B>PBC program executed according to plan</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 25.15pt; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.7pt 0pt 25.15pt; color: #232323">Patient enrollment for the ELATIVE<FONT STYLE="font-size: 10pt">&reg;</FONT>
Phase 3 trial evaluating elafibranor in PBC was completed mid-2022. Throughout 2022 GENFIT and Ipsen stepped up their collaboration in
order to minimize the time to filing as well as prepare for the commercial launch next year, if approved.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.7pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">___________________________</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>1</SUP></FONT> <I>Amount is net
of cash in transit of &euro;0.3m, earmarked for payment in early January 2023</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323"><BR>
</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">Pipeline progress</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD>Acquisition of the clinical-stage biopharmaceutical company Versantis</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 25.15pt; color: #232323">In September 2022, GENFIT acquired clinical-stage
biopharmaceutical company Versantis based in Zurich (Switzerland), significantly expanding its pipeline. This acquisition has reinforced
GENFIT&rsquo;s position as a leader in ACLF and other severe liver diseases. Given the unmet need related to target diseases, it is expected
that the programs qualify for some of the expedited regulatory pathways provided by health authorities.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 25.15pt"><FONT STYLE="color: Black">Two Pipeline Days were organized
in October 2022 in Paris and New York, to present these programs in detail. A replay of these events is available here: https://ir.genfit.com/events/event-details/genfit-pipeline-day-nyc</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 25.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD>Assessment of Nitazoxanide (NTZ) in hepatic and renal impaired patients</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 70.1pt 0pt 0.35in; color: #232323">Two Phase 1 studies were conducted, aimed at providing insight
into NTZ pharmacokinetics and safety in the setting of hepatic impairment or renal impairment, in order to prepare for the launch of a
Phase 2 study in ACLF in the second half of 2023.</P>

<P STYLE="font-size: 10pt; margin: 0pt 70.1pt 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD>Orphan Drug Designation granted to GNS561 for the treatment of cholangiocarcinoma</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 70.1pt 0pt 25.15pt; color: #232323">In September 2022 the US Food and Drug Administration (FDA)
granted Orphan Drug Designation to GNS561 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma
(CCA).</P>

<P STYLE="font-size: 10pt; margin: 0pt 70.1pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD>Compelling results for NIS2+<FONT STYLE="font-size: 10pt">TM</FONT> in NASH</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 25.15pt; color: #232323">In October 2022, GENFIT announced the
development of NIS2+<FONT STYLE="font-size: 10pt">TM</FONT>, a next-generation technology for the diagnosis of at-risk NASH, and the
presentation of results on NIS2<FONT STYLE="font-size: 10pt">TM</FONT>+&rsquo;s clinical performance in three poster presentations at
The Liver Meeting&reg; 2022 organized by the AASLD<FONT STYLE="font-size: 9pt"><SUP>2</SUP></FONT>. The NIMBLE initiative of the FNIH<FONT STYLE="font-size: 9pt"><SUP>3
</SUP></FONT>highlighted in 2021 the strong and unique performance of NIS4&reg; technology in identifying patients with at-risk NASH.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 29.7pt"></TD><TD STYLE="width: 34pt">II.</TD><TD>2023 Anticipated Milestones</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F"><B>Topline Phase 3 data for elafibranor in PBC:
towards the end of 2Q23</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 25.15pt; color: #232323">Topline results for the ELATIVE&reg; study
are now imminent and expected to be announced towards the end of the second quarter of 2023.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.45pt 0pt 0.35in; color: #232323">Phase 2 results showed a statistically
significant improvement on both the primary and composite biochemical evaluation criteria, the latter now being the primary endpoint of
the pivotal Phase 3 trial to support accelerated approval. In addition, the results showed a positive trend on the improvement of pruritus,
while preserving a favorable safety and tolerability profile. These</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.45pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">___________________________</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>2</SUP></FONT> <I>American Association
for the Study of Liver Diseases</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 25.15pt; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>3</SUP></FONT> <I>Non-Invasive
Biomarkers of Metabolic Liver Disease of the Foundation for the National Institutes of Health&rsquo;s Biomarkers Consortium</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 25.15pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 25.15pt; font-size: 10pt; color: #232323"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 25.15pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.7pt 0pt 0.35in; color: #232323">positive conclusions were published in
the <I>Journal of Hepatology</I> in 2021.<FONT STYLE="font-size: 9pt"><SUP>4</SUP></FONT> Safety data derived from more than 1,000 patients
in the biopsy-based Phase 3 RESOLVE-IT&reg; trial of elafibranor in NASH also supported further development in PBC.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.7pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 25.15pt; color: #232323">Under the agreement with Ipsen, GENFIT
is eligible to receive regulatory, commercial, and sales-based milestone payments up to &euro;360 million, with a potential first significant
milestone payment as early as 2023 and an additional potential milestone payment in 2024, if ELATIVE&reg; is successful. In addition,
GENFIT is eligible for double-digit royalties of up to 20%. In the case of a positive trial outcome, the well-established global commercial
footprint of Ipsen will be an important driver of commercial success. By 2024, if approved, elafibranor could potentially become a new
therapeutic option for PBC patients not responding to UDCA<FONT STYLE="font-size: 9pt"><SUP>5</SUP></FONT>, and become the first alternative
to currently approved second line treatment in a market estimated at $1.5bn in the coming years, and $3.1 billion in the US and in the
five main European countries by 2030.<FONT STYLE="font-size: 9pt"><SUP>6</SUP></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">Additional clinical programs
underway</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD>1st patient screening in a Phase 2 study evaluating VS-01 in ACLF: 2Q23</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.35pt 0pt 25.15pt; color: #232323">An international Phase 2, open-label,
randomized, controlled, multi-center, proof of concept study will assess the efficacy, safety and tolerability of VS-01 in addition to
standard of care (SOC), compared to SOC alone, in approximately 60 adult patients with ACLF grades 1 and 2 and who also have ascites.
A Phase 1 trial highlighted the favorable safety and tolerability profile of VS-01 and provided encouraging preliminary efficacy results,
with &gt;80% of treated patients improving or stabilizing their disease (Child- Pugh Score assessment). It is anticipated that the first
patient will be screened in this trial in the second quarter of 2023. Given the high unmet need in this indication and the Orphan Drug
Designation obtained from the FDA for VS-01, it is expected that the program qualifies for some of the expedited regulatory pathways provided
by health authorities.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.35pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">The overall market size of ACLF is estimated
to be almost $4 billion in the US and in the five main European countries by 2030.<FONT STYLE="font-size: 9pt"><SUP>7</SUP></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD>NTZ Phase 1 outcome in ACLF: May 2023</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">GENFIT is developing a second program in
ACLF in which it is evaluating NTZ. Two Phase 1 studies were completed in the fourth quarter of 2022 and the first quarter of 2023, and
are expected to provide preliminary insight into NTZ pharmacokinetics and safety in the setting of hepatic impairment or renal impairment.
Outcome of both the hepatic impairment study and the renal impairment study will be announced in May 2023. A Phase 2a proof of concept
study in patients with ACLF grades 1 and 2 is currently under discussion with the FDA, and study initiation is targeted for the second
half of 2023.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #E99D24"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-weight: normal">&ndash;</FONT></TD><TD STYLE="padding-right: 82.3pt">1st patient screening in a Phase 1b/2a study evaluating GNS561 in cholangiocarcinoma (CCA): targeted
towards the end of 2Q23</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 0.35in; color: #232323">A Phase 1b/2a trial will evaluate GNS561
in patients with advanced KRAS mutated CCA. In the Phase 1b, patients will be enrolled to evaluate the safety and tolerability of GNS561
when given in combination with a MEK inhibitor, and to identify the recommended doses of the combination to be administered in the Phase
2a study. GENFIT targets to screen the first patient towards the end of the second quarter
of 2023. Given the high unmet need in this indication and the Orphan Drug Designation obtained from the FDA for GNS561, it is expected
that the program qualifies for some of the expedited regulatory pathways provided by health authorities.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.55pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">___________________________</P>

<P STYLE="margin: 0pt 70.55pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>4</SUP></FONT> <I>Schattenberg
JM et al. J. Hepatol. 2021, 74(6), 1344-1354</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>5</SUP></FONT> <I>Ursodeoxycholic
acid</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>6</SUP></FONT> <I>IQVIA forecast</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>7</SUP></FONT> <I>IQVIA forecast</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.7pt 0pt 25.15pt; color: #232323"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.7pt 0pt 25.15pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.7pt 0pt 25.15pt; font-size: 10pt; text-align: justify; color: #232323"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 70.7pt 0pt 25.15pt; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px">&nbsp;</P>

<P STYLE="margin: 0pt 70.7pt 0pt 25.15pt; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.7pt 0pt 25.15pt; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.45pt 0pt 0.35in; color: #232323">The overall market size of CCA is estimated
to be more than $3 billion in the US and in the five main European countries by 2030.<FONT STYLE="font-size: 9pt"><SUP>8</SUP></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.45pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">Preclinical programs</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">In addition to clinical programs, GENFIT is
also pursuing the development of two preclinical programs:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt">&ndash;</TD><TD STYLE="text-align: justify; padding-right: 70.6pt">VS-01-HAC is a potential first-line lifesaving treatment for acute hyperammonemic
crisis associated with Inborn Errors of Metabolism in Urea Cycle Disorders (UCD) and Organic Acidemias (OA). Investigational New Drug
(IND) enabling nonclinical studies are targeted to be completed in 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18pt">&ndash;</TD><TD STYLE="text-align: justify; padding-right: 70.4pt">VS-02-HE is developed in Hepatic Encephalopathy (HE), which is one of the major
complications of advanced liver disease and portal hypertension. As many as 45% of patients with cirrhosis will experience at least one
episode of HE. VS-02-HE is a urease inhibitor, and a hydroxamic acid derivative, designed to inhibit ureases by binding to nickel atoms
in their active site. IND enabling nonclinical studies are targeted to be completed in 2025.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 0.35in; color: #232323">Although these are early-stage programs,
they represent a significant potential due to the high unmet medical need. Market size for severe hepatic encephalopathy (HE) alone is
estimated to be $3 billion in the US and in the five main European countries by 2030.<FONT STYLE="font-size: 9pt"><SUP>9</SUP></FONT>
For UCD and OA, estimations for 2030 go as high as $1.1 billion in the US and in the five main European countries.<FONT STYLE="font-size: 9pt"><SUP>10</SUP></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><TR STYLE="vertical-align: top">
<TD STYLE="width: 29.7pt"></TD><TD STYLE="width: 34pt">III.</TD><TD>Financial results<FONT STYLE="font-size: 10pt">(*)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">___________________________</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>8</SUP></FONT> <I>IQVIA forecast</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>9</SUP></FONT> <I>IQVIA forecast</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323"><FONT STYLE="font-size: 9pt"><SUP>10</SUP></FONT> <I>IQVIA forecast</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; color: #232323">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border-bottom: black 1pt solid; padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>(in &euro; thousands, except earnings per share data)</I></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><B>31/12/2021</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>31/12/2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Revenues and other income</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>85,579</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>26,566</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Research and development expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(35,166)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(35,818)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">General and administrative expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(16,153)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(16,405)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Marketing and market access expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(1,539)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(992)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Reorganization and restructuring income (expenses)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(142)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other operating expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(763)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(652)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Operating income (loss)</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>31,816</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(27,289)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Financial income</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">44,780</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">8,212</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Financial expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(7,122)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(4,758)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Financial profit (loss)</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>37,658</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>3,453</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Net profit (loss) before tax</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">69,474</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(23,836)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Income tax benefit (expense)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(2,215)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">116</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Net profit (loss)</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>67,259</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(23,719)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Basic/diluted earnings (loss) per share (&euro;/share)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">1.51</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(0.48)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Diluted earnings (loss) per share (&euro;/share)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">1.23</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(0.48)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Cash, cash equivalents and current financial assets</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">258,756</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">140,551</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323"><I>(*) Financial statements are not audited.
The audit procedures by the Statutory Auditors are underway.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">Revenues and other incomes</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 137.2pt 0pt 0.35in; color: #232323">Revenue and other operating income for
2022 amounted to &euro;26.6 million compared to &euro;85.6 million for 2021. In 2022, our revenue totaled &euro;20.2 million and came
from three streams related to Ipsen:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 137.2pt 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify; padding-right: 70.5pt">In December 2021, we received a &euro;120m non-refundable upfront payment from
Ipsen as part of our Collaboration and Licencing agreement. &euro;80m was recognized as revenue in 2021, and &euro;40m was booked as deferred
revenue and is gradually recognized as revenue in subsequent periods following the progress of the ELATIVE&reg; double-blind study. As
such, of that initial &euro;40m in the deferred revenue balance, &euro;15.9m was recognized as revenue in 2022.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify; padding-right: 70.55pt">&euro;3.3 million was recognized as revenue in 2022 in accordance with the Inventory
Purchase Agreement signed with Ipsen, pursuant to which Ipsen purchased inventory of elafibranor active pharmaceutical ingredient and
drug product during the second half of 2022, with the prospect of transferring the conduct of the ELATIVE&reg; study to Ipsen.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify; padding-right: 70.55pt">&euro;1.0 million in revenue was generated from the services rendered by GENFIT
to Ipsen in accordance with the Transition Services Agreement signed in 2022, which essentially outlines the scope of services to facilitate
the transition of some activities related to the Phase 3 clinical trial evaluating elafibranor in PBC.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">In 2022, other operating income totaled
&euro;6.4 million. This included mainly the research tax credit (known as Cr&eacute;dit d&rsquo;Imp&ocirc;t Recherche or CIR) granted
by the French tax authorities, which amounted to &euro;6.0m. This is up from &euro;5.3 million for 2021. This is due to an increase in
our research activities in 2022.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.6pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323"><BR>
</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 70.6pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px">&nbsp;</P>

<P STYLE="margin: 0pt 70.6pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.6pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">Operating results and expenses</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.65pt 0pt 0.35in; color: #232323">Operating expenses for 2022 amounted to
&euro;53.9 million, compared to &euro;53.8 million for 2021. This is comprised of research and development expenses, general and administrative
expenses, marketing and market access expenses, reorganization and restructuring expenses, and other operating expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.65pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">The slight increase is due to multiple factors:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify; padding-right: 70.3pt">The increase in research and development costs of &euro;0.6 million, explained
by the increase in costs related to new programs and product candidates, in particular NTZ, VS-01 and GNS561, offset by the sharp reduction
in study costs related to RESOLVE-IT&reg;,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="padding-right: 70.4pt">The increase in general and administrative expenses of &euro;0.2 million, explained by the increase
in costs related to liability insurance, the increase in costs related to consulting fees, and other charges in the normal course of business,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="padding-right: 70.55pt">The decrease in marketing and market access expenses of &euro;0.5 million, mainly explained by the
decrease in marketing activity in the United States and France,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18.05pt">&bull;</TD><TD STYLE="padding-right: 70.35pt">The decrease in reorganization and restructuring charges of &euro;0.1 million (effectively null in
2022), and the decrease of other operating expenses of &euro;0.1 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.65pt 0pt 0.35in; color: #232323">In 2022, GENFIT generated a consolidated
operating loss of &euro;27.3 million, compared to an operating income of &euro;31.8 million in 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.65pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">Financial results</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">2022 resulted in a financial income of &euro;3.5
million compared to a financial income of &euro;37.7 million in 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 0.35in; color: #232323">In 2022, financial income is due to net
foreign exchange gains of &euro;7.1 million, interest income of &euro;0.7 million, offset by interest expense of &euro;4.3 million.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">In 2021, financial income was due to net
foreign exchange gains of &euro;6.7 million, interest income of &euro;0.3 million, offset by interest expense of &euro;4.9 million. In
addition, the company recorded a one time gain of 35.6 million corresponding to a repurchase bonus following the renegotiation of the
OCEANEs in January 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.5pt 0pt 0.35in; color: #232323">The foreign exchange result on cash and
cash equivalents was a net gain of &euro;7.1 million in 2022, compared to &euro;6.7 million in 2021. This is notably due to the difference
in currency exchange recognized on cash and other current financial assets in US dollars, as GENFIT has decided to keep some of its cash
in US dollars. These cash and other current financial assets in US dollars are to be used to pay directly expenses in US dollars (natural
currency hedge).</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.5pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">Cash position</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 0.85in; color: #56879F">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">As of December 31, 2022, the Company&rsquo;s
cash and cash equivalents and current financial assets amounted to &euro;140.6 million compared with &euro;258.8 million as of December
31, 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.6pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323"><BR>
</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 70.6pt 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">This is mainly the result of the following, in addition to normal
business activity:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="padding-right: 70.6pt">The payment of &euro;24.0 million in January 2022 representing the VAT collected on the initial upfront
payment received from Ipsen in December 2021,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="padding-right: 70.65pt">The disbursement of employee participation in the profits of GENFIT SA in May 2022 for a total of &euro;0.6
million for the financial year 2021, and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; color: #232323"><TR STYLE="vertical-align: top">
<TD STYLE="width: 43.15pt"></TD><TD STYLE="width: 18.05pt">&bull;</TD><TD>The acquisition of Versantis AG totaling &euro;41.5m net of cash acquired.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 78.7pt 0pt 33.2pt; color: #005478"><B>GENFIT will host a conference call in
English and in French on April 14, 2023 at 8.00am ET / 1:00pm GMT / 2:00pm CET</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 78.7pt 0pt 33.2pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in"><FONT STYLE="color: Black">Both the English and French
conference calls will be accessible on the investor page of our website, under the &lsquo;Events and presentation&rsquo; section at https://ir.genfit.com
or by calling <B>888-394-8218</B> (toll-free U.S and Canada), <B>0800-279-0425</B> (toll-free UK) or <B>0805 101 219</B> (toll-free France)
five minutes prior to the start time (confirmation code: <B>8860599</B>). A replay will be available shortly after the call.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.6pt 0pt 0.35in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 78.55pt 0pt 33.2pt; color: #232323"><B>APPENDICES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 78.55pt 0pt 33.2pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 0pt 0 0pt 0.35in; color: #E99D24">Statement of Operations*</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 0pt 0 0pt 0.35in; color: #E99D24">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 44.3pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #232323"><B><U>Year ended</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border-bottom: #232323 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>(in &euro; thousands, except earnings per share data)</I></FONT></TD>
    <TD STYLE="width: 15%; border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">31/12/2021</FONT></TD>
    <TD STYLE="width: 15%; border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>31/12/2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Revenues and other income</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Revenue</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">80,069</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>20,195</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other income</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">5,510</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>6,371</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Revenues and other income</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>85,579</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>26,566</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Operating expenses and other operating income (expenses)</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Research and development expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(35,166)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(35,818)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">General and administrative expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(16,153)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(16,405)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Marketing and market access expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(1,539)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(992)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Reorganization and restructuring expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(142)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>11</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other operating income (expenses)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(763)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(652)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Operating income (loss)</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>31,816</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(27,289)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Financial income</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">44,780</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>8,212</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Financial expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(7,122)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(4,758)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Financial profit (loss)</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>37,658</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>3,453</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Net profit (loss) before tax</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>69,474</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(23,836)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Income tax benefit (expense)</FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(2,215)</FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>116</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Net profit (loss)</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>67,259</B></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(23,719)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Basic and diluted earnings (loss) per share</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Basic earnings (loss) per share (&euro;/share)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">1.51</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(0.48)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Diluted earnings (loss) per share (&euro;/share)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">1.23</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>(0.48)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323"><I>*Unaudited financial statements. The audit
procedures by the Statutory Auditors are underway.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.35in; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.35in; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; color: #B6B6B6; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; color: Gray">Appendices</FONT></P>

<P STYLE="font-size: 10pt; text-indent: 266.6pt; color: #B6B6B6; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 0pt 0 0pt 70.8pt; color: #E99D24">Consolidated Statement of Financial
Position*</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 0pt 0 0pt 70.8pt; color: #E99D24">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323"><B>Assets</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 34.35pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #232323"><B><U>As of</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border-bottom: #232323 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>(in &euro; thousands)</I></FONT></TD>
    <TD STYLE="width: 15%; border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><B>31/12/2021</B></FONT></TD>
    <TD STYLE="width: 15%; border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>31/12/2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Current assets</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Cash and cash equivalents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">258,756</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">136,001</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Current trade and others receivables</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">7,236</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">15,906</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other current financial assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">0</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">4,550</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other current assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">2,101</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">1,998</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Inventories</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">4</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Total - Current assets</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>268,097</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>158,459</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Non-current assets</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Intangible assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">174</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">43,957</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Property, plant and equipment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">9,015</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">8,210</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Non-current trade and other receivables</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">3</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">0</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other non-current financial assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">4,431</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">4,914</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Total - Non-current assets</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>13,623</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>57,081</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Total - Assets</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>281,720</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>215,540</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323"><I>*Unaudited financial statements. The audit procedures by the Statutory
Auditors are underway.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; color: #B6B6B6; margin-top: 0pt; margin-bottom: 0pt">Appendices</P>

<P STYLE="font-size: 10pt; text-indent: 266.6pt; color: #B6B6B6; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323"><B>Liabilities</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-left: 30.15pt; text-align: center"><FONT STYLE="font-size: 10pt; color: #232323"><B><U>As of</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border-bottom: #232323 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>(in &euro; thousands)</I></FONT></TD>
    <TD STYLE="width: 15%; border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><B>31/12/2021</B></FONT></TD>
    <TD STYLE="width: 15%; border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>31/12/2022</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Current liabilities</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Current convertible loans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">415</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">415</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other current loans and borrowings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">1,773</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">4,665</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Current trade and other payables</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">40,988</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">14,845</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Current deferred income and revenue</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">14,298</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">14,479</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Current provisions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">313</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other current tax liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">5,051</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">4,906</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Total - Current liabilities</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>62,837</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>39,370</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Non-current liabilities</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Non-current convertible loans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">47,682</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">49,861</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Other non-current loans and borrowings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">24,365</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">20,334</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Non-current trade and other payables</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">450</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">448</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Non-current deferred income and revenue</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">25,821</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">9,706</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Non-current employee benefits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">864</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">782</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Deferred tax liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">602</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">510</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #232323 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Total - Non-current liabilities</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>99,786</I></FONT></TD>
    <TD STYLE="border-bottom: #232323 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>81,641</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Shareholders' equity</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Share capital</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">12,454</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">12,459</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Share premium</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">444,438</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">444,683</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Retained earnings (accumulated deficit)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(405,076)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(337,550)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Currency translation adjustment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">22</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(1,344)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Net profit (loss)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">67,259</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(23,719)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Total - Shareholders' equity</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>119,097</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>94,528</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>Total - Shareholders' equity &amp; liabilities</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>281,720</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>215,540</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323"><I>*Unaudited financial statements. The audit procedures by the Statutory
Auditors are underway.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt; color: #B6B6B6">Appendices</P>

<P STYLE="font-size: 10pt; text-indent: 266.6pt; color: #B6B6B6; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 0pt 0 0pt 70.8pt; color: #E99D24">Statement of Cash Flows*</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-indent: 0in; margin: 0pt 0 0pt 70.8pt; color: #E99D24">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 71%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 15%; padding-left: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><B>Year ended</B></FONT></TD>
    <TD STYLE="width: 14%; padding-left: 9.75pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><B>Year ended</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>(in &euro; thousands)</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><B>2021/12/31</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F"><B>2022/12/31</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Cash flows from operating activities</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Net profit (loss)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">67,259</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(23,719)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Reconciliation of net loss to net cash used in operating activities</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Adjustments for:</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Depreciation and amortization on tangible and intangible assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">2,742</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">1,832</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Impairment and provision for litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(1,996)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(179)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Expenses related to share-based compensation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">470</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">245</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Gain on disposal of property, plant and equipment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">420</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(16)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Net finance expenses (revenue)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">4,663</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">2,042</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Income tax expense (benefit)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">2,215</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(116)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Other non-cash items</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(35,538)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">2,210</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12.1pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">including Income incurred by renegotiating the convertible bond debt</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Operating cash flows before change in working capital</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>40,235</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(17,702)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Change in:</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Decrease (increase) in trade receivables and other assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">4,344</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(8,565)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">(Decrease) increase in trade payables and other liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">55,335</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(46,226)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Change in working capital</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>59,680</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(54,791)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Income tax paid</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">0</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(145)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Net cash flows provided by (used in) in operating activities</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>99,915</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(72,638)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Cash flows from investment activities</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.15pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Acquisition net of cash acquired</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(41,525)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Acquisition of property, plant and equipment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(537)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">251</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Proceeds from disposal of / reimbursement of property, plant and equipment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">309</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Acquisition of financial instruments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(3,148)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(5,012)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Net cash flows provided by (used in ) investment activities</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(3,377)</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(46,266)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #DF6803 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #F5821F"><I>Cash flows from financing activities</I></FONT></TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: #DF6803 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Proceeds from issue of share capital (net)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">27,972</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Proceeds from new loans and borrowings net of issue costs</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">15,270</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">0</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Repayments of loans and borrowings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(48,436)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(628)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Payments on lease debts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(1,887)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(1,120)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">- Financial interests paid (including finance lease)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">(2,109)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(2,180)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.6pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">+ Financial interests received</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">274</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">137</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Net cash flows provided by (used in ) financing activities</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(8,916)</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(3,786)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Increase (decrease) in cash and cash equivalents</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>87,622</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>(122,690)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Cash and cash equivalents at the beginning of the period</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">171,029</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">258,756</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323">Effects of exchange rate changes on cash</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #3B3B3A">105</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: #F5821F">(65)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 3.45pt; text-align: left"><FONT STYLE="font-size: 10pt; color: #232323"><I>Cash and cash equivalents at the end of the period</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>258,756</I></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt; color: #232323"><I>136,001</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323"><I>*Unaudited financial statements. The audit procedures by the Statutory
Auditors are underway.</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 70.8pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; color: #232323">&nbsp;</P>

<P STYLE="text-align: center; font-size: 10pt; color: #B6B6B6; margin-top: 0pt; margin-bottom: 0pt">Appendices</P>

<P STYLE="font-size: 10pt; text-indent: 266.6pt; color: #B6B6B6; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 70.8pt; color: #005478">ABOUT GENFIT</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 70.8pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.65pt 0pt 70.75pt; color: #232323">GENFIT is a late-stage biopharmaceutical
company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT
is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today
GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.65pt 0pt 70.75pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 70.75pt; color: #232323">Its R&amp;D pipeline covers six therapeutic
areas via six programs which explore the potential of differentiated mechanisms of action, across a variety of development stages (pre-clinical,
Phase 1, Phase 2, Phase 3). These diseases are acute on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma
(CCA), urea cycle disorder (UCD), organic acidemia disorder (OAD) and primary biliary cholangitis (PBC). Beyond therapeutics, GENFIT&rsquo;s
pipeline also includes a diagnostic franchise focused on NASH and ACLF.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 70.75pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.35pt 0pt 70.75pt; color: #232323">GENFIT has facilities in Lille and Paris
(France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market
and on compartment B of Euronext&rsquo;s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT&rsquo;s
largest shareholders and holds 8% of the company&rsquo;s share capital. www.genfit.com</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.35pt 0pt 70.75pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 70.8pt; color: #005478">GENFIT FORWARD LOOKING STATEMENTS</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 70.8pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.55pt 0pt 70.75pt; color: #232323">This press release contains certain
forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform
Act of 1995 in relation to its timelines for topline data readout for our ELATIVE&reg; Phase 3 trial, potential for positive
ELATIVE&reg; Phase 3 results, eligibility to meet milestones and receive payments from Ipsen, timelines for data readout in NTZ in
ACLF Phase 1 trials, timelines for patient screening and enrollment in our VS-01 ACLF and GNS561 in CCA programs, timelines for the
initiation of a Phase 2a proof of concept study evaluating NTZ in patients with ACLF grades 1 and 2, the potential for VS-01-HAC to
be a first-line life-saving treatment, the completion of IND enabling nonclinical studies in VS-01-HAC and VS-02-HE, the future of
NIS2+<FONT STYLE="font-size: 10pt">TM, </FONT>commercial perspectives for elafibranor and its potential as a therapeutic option for
patients, potential market sizes in the disease areas where we develop our product candidates, our ability to qualify for and obtain
specific regulatory pathways, our financial outlook including cash flow and cash burn projections and business activity projections
for 2023 and beyond. The use of certain words, including &ldquo;consider&rdquo;, &ldquo;contemplate&rdquo;, &ldquo;think&rdquo;,
&ldquo;aim&rdquo;, &ldquo;expect&rdquo;, &ldquo;understand&rdquo;, &ldquo;should&rdquo;, &ldquo;aspire&rdquo;,
&ldquo;estimate&rdquo;, &ldquo;targeted&rdquo;, &ldquo;anticipated&rdquo;, &ldquo;believe&rdquo;, &ldquo;wish&rdquo;,
&ldquo;may&rdquo;, &ldquo;could&rdquo;, &ldquo;allow&rdquo;, &ldquo;seek&rdquo;, &ldquo;encourage&rdquo; or &ldquo;have
confidence&rdquo; or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar
to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on
reasonable expectations and assumptions of the Company&rsquo;s management, these forward-looking statements are subject to numerous
known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied
or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties
inherent in research and development, including in relation to safety, biomarkers, cost of, progression of, and results from, its
ongoing and planned clinical trials, review and approvals by regulatory authorities in the United States, Europe and worldwide, of
our drug and diagnostic candidates, exchange rate fluctuations, potential synergies related to the acquisition of Versantis, our
capacity to integrate its assets, develop its programs and our continued ability to raise capital to fund our development, as well
as those risks and uncertainties discussed or identified in the Company&rsquo;s public filings with the AMF, including those listed
in Chapter 2 &ldquo;Main Risks and Uncertainties&rdquo; of the Company&rsquo;s 2021 Universal Registration Document filed with the
AMF on April 29, 2022 under n&deg; D.22-0400, which is available on the Company&rsquo;s website (www.genfit.com) and on the website
of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission
(&ldquo;SEC&rdquo;) including the Company&rsquo;s 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 and the 2022
Half-Year Business and Financial Report. In addition, even if the Company&rsquo;s results, performance, financial condition and
liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may
not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of
publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or
revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 70.4pt 0pt 70.75pt; color: #232323">&nbsp;</P>

<P STYLE="margin: 0pt 70.4pt 0pt 70.75pt; font-size: 10pt; text-align: justify; color: #232323"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 70.4pt 0pt 70.75pt; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323"><IMG SRC="logo.jpg" ALT="" STYLE="height: 175px; width: 800px"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center; color: #232323"><FONT STYLE="color: #999999">Appendices</FONT></P>

<P STYLE="margin: 0pt 70.4pt 0pt 70.75pt; font-size: 10pt; text-align: justify; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 70.8pt; color: #005478">CONTACT</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0 0pt 70.8pt; color: #005478">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 70.8pt; color: #232323"><B>GENFIT</B> | Investors</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 70.75pt"><FONT STYLE="color: #232323">Investors Relations | Tel : +1
(617) 714 5252 </FONT><FONT STYLE="color: Black">| investors@genfit.com</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323"><B>PRESS RELATIONS</B> | Media</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.8pt; color: #232323">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.75pt"><FONT STYLE="color: #232323">Stephanie BOYER &ndash; GENFIT | Tel : 03 20 16 40
00 </FONT><FONT STYLE="color: Black">| stephanie.boyer@genfit.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>
<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 95%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 21px; width: 500px"></TD><TD STYLE="text-align: right; width: 5%">12</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+!,(# 2(  A$! Q$!_\0
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M1K@Q/QGJX/\ AOU"BBBN8[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=;'G_A3X>0>)M&%\E[Y>7*[2#VJ_J/PNT_3%5KO5?+#=/D)S72_"4A?" W$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^9*E6H,G-3)7J2/ CN2T_C%
M,!I2PK(Z!<BHV:@L*:QS6D3*8QFJWI!DDOQ&E\;,%23(&Q5%JJRMUK5JZL91
M=G<[G4=+UBQ$2)KLLL\VTQQ"0_,#T/6LR\T[Q;:VYF>^D90X4E+K=M^N#Q5*
MX\6M+J]A?+;!3:1I'MW9W!0!^'2K%WXO@.FWEI96#0&[;?)(]P7QUZ ].M<Z
M4NQU.47U(7T_QEF0+<WA\MU4XF8\L,C]*J6MOXNO+VZM8+R[>2U&Z0B<X'M]
M>:VXOB=>VX@"VD;*D/EL"?OGLW3L.*SM'\?S:):NEK9J9II#)-*[9+GTY''%
M4N:VQ#4+_$RG8:3XH\3VDPBN9)H8WV.L\^!G\:JP>#=8N-1N;%8HUEME#2%Y
M JX)QD$]>:W+/XC-IINVLM+BB-S-YK!GW < 8 Q[57?QM%/J>I7,^FN\=_&L
M;QI<%2N&W<$#BJYIJ]D1R4W:[U*2:%XETO48].A>6&:?YD$,IV-WSD<4NM#Q
M1H)C^W:E.OF9VE+@M_(UH/XV=[^QE33'%M9J41#.2QXQRV,U%XHU^;Q'9V\$
M6E"V6-BV=^\G..^..E*[;5T-QBHOE8SPM;>(/$\T\<.M7<9A&YB9&/\ 6I=9
M\/\ B#3=2L"NI337%T3'"[2%6!R!CKP*J>%==N/"\EP39?:5G7:=LA0C\0*O
MZKXPN+C4-*N!IC(EA)YBH92[/R#U(S4/FYM#6/+R:O4)]%\96AC6?5"K2.$4
M?;>_YU-)H'C*%D$NIE2_3-]U_6L[Q-XHBUU%DCTR2TN V1(+AB#ZC&/UJCK/
MB.?5I;9MKP>0@7 D)W>].,6^@2<5LS6N]$\5V5];B6\(NKAO*0I=98\9P>>G
M%5=4\+Z]'=P+?O'+<7#;%_?ASGKSZ4DGBZ27Q+:ZP;<X@(/DF0D-QC/M5Z_\
M;6EYJEMJ2:28Y[<YYN"01SVQ[T_>70FT'U(+_1_%'AJP$DES)%!G&(;C(4^^
M*3P_%K?BF[DL8]4N<["Q#2$@\'CK5C7_ ![+X@TAK&XLE5M^Y9$;;CIP0!S6
M3X;\0OX<O);B.'S)'B9%^;&TD$9]\9H2ERWMJ)N*E9/0UK'0_$D.GWSBZN+6
M"S)!4.0&(SG'Y5%-X=\3ZCIB7-Q<^9;,-Z^=<_T-2S_$.^N["2UN85=&B\OY
M3MYQ@L?6A_'5O-H,>F7.DF01H%$B7!4GCV%3[^]B_P!WT9GVW@77+N!9XHX<
M/D*!* QQZ#O3H(O$L5HABN;J./S?($:RG[W/&/PJ[9>.K:V%DYTJ4S6>1$XN
MF Y.>5QS3(O&4V$_T9=Z70N0V[KC/'ZU2<WHT)J"V8FI:-XAMX4EU&8SKN
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MF+'M-97U-[61*N:D#$4T4'Y:WCL<S5B0/2[JK&4 TX2BJ%<GW5$YH#@T'!H
MKLK$]*5=RU/CBDV@TFAD?F8IPDI&05$3BBP%@/09.*KAB33^2*S9M'8<9L5$
MT^XX%(ZD]*9''B09IJQ$D6%J=&J-5J0+3L),DW4N:C/%)FJ))<T;JBW49S5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[4&-%DW!MR^E1$D.=H(!H <$,<9?<0?2GB7S,;P"1WJ,R= >14B+$X(!VM0
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MRO)YK#)]!BLZDN579O2@YRY4SR7R\4H1O2O?#X-T3K]C7/T%>+ZA D6I74:
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MON:W/^$O^*'_ $"+W_P5M_\ $UI6C.4KQEIZF6'G3A!*<&WZ':?%S_D09_\
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MWZ]4>TP?#7PC;3QSQ:0%DC8.C?:)3@@Y'\5=77B/_"7_ !0_Z!%[_P""MO\
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M@0U,#6I@T!'%1L*E/2FFA 1 5(!3<TH-%QV'TUC2YIC&D.Q$Y.*@SDU,PS3
MG-#9-@V9%.5*>HXIP%18M/00+BGBB@4T2&,U&ZYJ84A%4!DW,&#D"FQ#BM&5
M-PJKY.TU<69R0]1Q3\@"FD8%02$^M,1/O&:>.:J)G-64Z5+E8T4;H?CBO7?A
MR,>%1_UV?^E>15Z]\.?^16'_ %W?^E<^(=XG5A5:9UAZ5\_:I_R%;S_KN_\
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M#52DD(-7KH<"J@CWMS5$6*QRQZ5/#".I%7$@4#I4PA7% [$21@5-M% 7%.)
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MI_Z+:O;JY:FYK1^$****S-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHFL7<24BJ3MS6R+56'-5I]/&W*TXRL)HRMU*&-++"T;8IN#6JU('AJ7)]:8
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M I<5*(Z4I76<,6T0FF&I'7%0DX/-1)&BDSI/ /\ R.^G_P#;3_T6U>W5XAX
M8'QOIP_ZZ?\ HMJ]OKBJ[GHT/A"BBBLC<**** "BBB@ HHHH **** "BBB@
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; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B SH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN3U?X
MC^&M&U![":\DGNX_]9%:PM*8_J0,#Z9HN!UE%<L_Q#\-KX:?7X[QIK!)1"YC
MC.]7/8J<$5'I'Q%T76M3AL+6'45FFSM,MHR+P">2>G2CR#I<ZVBL?P]XGTKQ
M1:S3Z7.9!#(8Y49=K(P]1[^M1+XNTIDUM@\N-&)%W^[Z8!/R^O -#T W:*X>
MU^*WAV]EA2"+4V\Y@J-]C;:<G'7TK1E\>:+%'JK_ .E/_9<ZV]RL<!8AV) P
M!U'!H Z>BN"7XO\ AEY'C2/4VD3[RBS8E?J.U=??ZG'8Z%<ZJ8V>.&W:XV="
M0%W8]C0]%<%J[%ZBHK:<7-I#< %1*BN >V1FL!_'.B)*V7N3:I+Y+7PMG-NK
MYQ@R8QUXST]Z;5G82=U<Z2BLG5?$5AI%Q#;2BXGNYU+QVUK"TLC*.K84<#W-
M.M/$.FWVCSZI!,QM[</YP9"KQ%!EE93@@CT-*^EQ^1J45S^D^+K;6;F&&WTS
M68UF7<D]Q821Q8QD'>1CGMZUT%%@"BL?1O$^E:]>ZA::?.9);"7RI@5P,Y(R
M/49!&?:MB@ HHHH **** "BBB@ HKDU^(&G2RSI;:9K=TL$K0O);:=)(F]3@
MC<!BNGM;@75I%<".6,2H'"2H4=<CHRGD'VHZ7#K8EHHHH **H:9J]KJIND@\
MQ);64PS12KM=&Z]/0CD'H:OT %%%% !16/K_ (GTOPTMHVISF,74PACPN>?4
M^@'<UL4 %%5=3OXM*TVXOIHY9(X$+LL*%W('H.]2VTZW5K#<(KJLJ!P'7:P!
M&>0>AH EHHJAI^L6NIW-Y#:^8XM)/)DEVX0OW53WQWQTH OT444 %%8FL^*+
M/1+V"SEMK^ZN9HVE6*RM6F8*" 20O09(I[>);"#03K%\+BPM0<%;N!HY,YP!
ML(SDGH,<T>8>1L45AZ/XKTS6KQ[*$75O>*GF?9[RW>%V3^\ P&1]*DN/$^DV
M_B.UT!KD-J5PI984&=H )^8]N <4 ;%%9.M>(]/T'R$NVF>>X)$-O;PM++)C
MKA5!.!ZTRR\5:-?:/<:JEV([6U)6X,R&-H6'4,I&0?:CS V:*Y_2?&>D:O?)
M90M=07$J&2!+JV>'ST'5DW ;A]*T=9UBTT'2IM2OBXMX=NXHNX\L%''U(H O
MT4@(8 CH>:6@ HHHH **** "BLC7_$=EX=BMGO([F1KF7R88[:$RN[X)P%'/
M:J]EXLMKS[06TS6+5((6F>2[L)(5VKU +#!/M1?J%C?HKDK;XC:'.MO++'J-
MI;7) ANKJRDCA<GIA\8Y]<XK?UC5[/0M)GU.^D*6T"@L5&2<G  '<DD4/35@
MM=$7J*IV.J6FHZ1#JEM)OM9HO.1L<[<9Z>M1:'KNG^(]*CU+3)_-MY,C.,%2
M.H([&BVM@\S1HK-L]=L+VUO;E)O+@LIY()WE^4*R?>.3V]ZQA\1- ($O^GBR
M)P+XV,HMS_P/;C'OTH ZNBN;U#QKI]AJ\NF+9ZG>7,,:R2"RLWF"JPR"2M:V
ME:FFK69N4M;RV&XKY=Y;M"_'?:W..>M %ZBL^TU5+O6=1TU8F5[(1%G)X;>"
M1CZ8J^2%!)( '<T +145Q<PVEK+<W$J101*7>1S@*HY)-8.F^.-%U2_@LXFN
MX7N03;/<VLD27 '/R,P /'-'6P>9T=%<[JGC71])OI;.4W<\L"AKC[+:O,+=
M3R"Y4$+QS5F^\4Z1I^EVNHR77FP7>!;"!&D><D9 15&2:.EP\C9HK)T3Q'I^
MOK.+-IDFMV"SV]Q"T4L1/(W*P!YJ36M>T_0;>.6^D<&5_+ABBC:225O154$D
MT/0-S2HK&TKQ1I6KVMW/#,\/V/\ X^H[J-H7@XS\ZL 0,<YJIIWCG0]3OH+6
M*2YC-R2+66XMI(H[C'_/-F #4=;!YG245CZWXHTGP_+:1:A<A)KN58H8E&YV
M).,X].>M:Y(4$D@ <DGM1TN M%9VC:W9Z]:R75@9'MED:-963:LA7@E?49[U
MH$@ DG '4F@!:*R-&\3:5KUK>75A<;[>TF:&25AM7*@$D$]1@]:HV7CS0;^]
M@MHI;E%N7V6UQ+;2)#.WHCD8)_G1Y =+16#J_B_2M&OOL4QNI[I4\R2*TMGF
M:)/[S[0=H^M3S>)]&AT!-<:^C.G2 %)5!.\DX"@ 9+9XQC-'2X>1KT5BZ-XI
MTW7+F6UMS<0W<2AWMKN!H9 IZ-M8#(]Q5K4]633)M/C>)G-[="V4@XVDJS9/
M_?- &A1110 4444 %%%% !1110 4444 %%9NL:[9:'' UT96DN)/+@A@B:22
M5L9PJCD\<TVSUZUO+J]MQ#=0-9HCRM/"47#+NX)ZX'7TH U**AM+J"^M(;NV
MD$D$R"2-P/O*1D&IJ "BBB@ HHHH **** *VH&==-NC;#,XA<QC_ &L''ZUY
M[\)&B@^'<UW96PNM5,LK7,>\+))*"=JECTXQU]:]+KCM1^&VC7NIS:C:76IZ
M3<SG,S:;=&$2'U(P1^5+9OS'NEY'#>-O$H\0?#K6D.D#3+BRU..&>+S%?,F>
M22H )]^:]'\/2^*7.-;MM*BM1"/+:TE=G+<8R& &,9K/D^&.@OX9N-"62^2&
MYG6XGG$P::1QW)8$?I4^D>!$TC4H+Q?$WB2[$6<07=_YD39!'*[1GK3Z-?UM
M8E]'Z_F>7>%+/4?#NAKXVT</,L5U-%J=F#_K8 _WA[K_ )[YU](U"VU;1/B;
MJ%H^^WN 9(VQC(,;5Z=X=\-V7AK26TVT>:6!I'D)G(8DL<D< #'X5FV'P^T7
M3-/UNQLS<Q6VL9$R!UQ$"",1\<=3US2DKIKRM^7^1:?O7\[_ (O_ #.<^'%W
MXP_X1_0X?[,TW^QO+ \_SCYNSGG;TS4_PY_Y'#QW_P!A%?YO7;Z)I%OH.BVF
MEVKR/!;1B-&E(+$>^ !^E5-%\,66A:EJU]:RW#RZI,)YA*RE589^[@# ^8]<
MU;?O-^OZ?Y$)6C;T_4Y+PA_R5SQM](/_ $&NN\7?\B9K?_7A-_Z :;IOA>RT
MOQ%JFMP2W#7.I;/.1V4HNT8&T  C\2:G\26LU[X7U6UMHS)/-:2QQH#]YBA
M'YUE/^';R_S+C_$OY_Y$NGR)%H%K)(<(EJC,?8*,UY8L.M2?#"<P);#PNQ>8
M1LQ^V?9=Y8C/W-W7'M[UZQ80M'I5K!*F&6!$=3SSM (KGCX T_[*U@NHZHFD
MLQ)TY9P(<$Y*_=WA<]MV*UG\<FOZUN1#2,?ZZ&3<7%S?>.K*;PP(/M*:2IN&
MO<^5Y#MF, +\V_(SZ8IOA_3I=5TCQ=H=U/\ 9M9N+EQ?31KOB!D0;3&,@[=H
MZ'GKFNFU#PK9WE]#?6US=Z;>10^0)K)U4M&.B$,K*0.W'%);^$=/MM*O+%)[
MW?>2>;<7?VAA/(_&&WC&,8' X]JEVU^?YW&M+?+\$8T-QKOA?7M%TR^U.'4[
M#4"UN@%J(9(&5,@C:2"N!@YZ5L^,M;/A_P *WU]&"UQL\NW4#):5OE4 =^3G
M\*;IGA&TT_4TU&>_U'4KR)"D,M_.)/)!Z[0  ">YQFKNJ:';:Q=Z=/=238L)
M_M$<2D!'<# +#&3C.1@BB7O*S_K^OU".CNOZ_K0\UTJ[TWPSK7AF2R-YL>#^
MSM1>:QFA5F8[E<LZ 9\PGOG#5N3>*+_0['Q'IMU,UQJEK.!IQ<#=*LYQ#]=K
M$@_[M=AKFC6OB#1[C3+PR"&8#+1D!U(((*D@X((%4KSPEIM_KNF:Q<M.]WIZ
M;4.X8D]"XQR022,8Y-&^_P#2>OYZ>C\@VV_I_P#!_0Y.;5-<?7)=",VM2IIE
MK!YTVF)"9)IG7)9S)T7T 'KFI+G5?$[67ARVN9Y].O+K4I+625XDWR1;&*L4
M&5#$ 'TR/3BNKU+PS;W^IC4X+V]T^^\ORGGLW53(@.0&#*RG'.#C-(WA>UD&
ME&:[OIGTVX-S')+-O:1R"#O)'3YCP,8H7G_6K#T_K0Y;4-3U;0KGQ+I0U6YN
MU@T8W]M/<!/-B?YE(RJ@$9 /(XK2U75K^#0_"$T5RZR7E]9QW##'[Q77+ _6
MMNX\-V%UK%WJ4_FR/=67V&6(D>68\D],9SR>]9L7@2S0:>LNJ:M<1Z=/'-:Q
MS3J5C*'@8"C([<Y..A%"Z7\OU_X _3S_ "7_  3 FUS6]8UC61;_ -NQ0V-R
MUK;+IL-NR;E RTGF'+$D].!BNYT*XO[K0K*;5+?[/?O$//B_NOWZ?G6?=>$[
M>74KB^L]2U'39;K!N!9RJJRD#&XAE;!QQD8-;=K;K:VL5NKRNL:A0TKEW;'<
ML>2?>A;6$]SS;P2?% MM5_LJ/1S9_P!KW.3=/*),[^?N@C%=18:A=R_$36-/
MDG9K6&RMY(XNRLQ;)'UP*K0^ 8[22Y-EXDUZTCN)WG:*&>(*'<Y.,QFKL_A&
M"6\@O8]5U.WO4MUMI;B&5 ]P@Y'F94@G.>0 >:%HEZ?HD#U;]?UN<F?$>K#P
MZTTNH3Q0MK\UI<74<8>6& ,0H1<')S@="1FGCQ!K.DZ/XCUB*^OM0TVTC1-.
M:]MUC,CM@,Q^168*3C/ //UJWK7A#^S=.T^TTZ#4;K3X]1>]N?(G'VI&(.TQ
ML2"0">>=V.YJUHFDWM_>:A#?1ZHWA^XM?)-MJ\H>1Y">67!)5=O')Z_2DEI;
M^ME_D[>H[ZW_ *W?_ N5=)N?$<6L:>PAUVXBG?;?G4(;=8U7:?G3RSE<'''(
MP?6LN#4/$#?#RY\4MXANOM-H\K1P"./RF5)2NUQMRV0.N1CC\>WTWPP-.G@?
M^VM7N(;<8BMY[@%%&, ':H+8']XFF)X/T^/PC/X;$UU]CG$@9RR^8-[%C@[<
M=3Z4WY?UK_D)=+_UH<[JWB'5-0\3?V7:IJT=K#917$G]EI"97>3.,M(>% '8
M<FNE\)W&KW&D/_;,,T<\<[I&TZ(LDL0QM9@A*@\X./2B]\*VMU<VUW!>7MC>
MP0BW%S:R*'>,?PL&4JPSSR*T=.T\:=9_9Q=75R<EC-<R^8Y)]^@^@ 'M3TUM
M_6O^0M=+_P!:?YGG&M7NE>(?&&M0ZF+IK*RLVT^W,-E-.OG/S(^40@%?E%36
M'BG4/^$.T36C/*O]F70L]7A92-R?<+L",@C*MVZFNZT+0[7P_IOV*U>613(\
MKRS$%Y'8DEF( &>?2JW_  BNG&;6G)F,>L*%NH"PV9"[=RC&02.O)Z"DM%_6
M^_XW:^XIZO\ K;;_ "?WG-ZQKNI7$7B[4;"\>*RTNS:VM]F,-< ;G?\ X#E5
M_.GO=:MJ?BK2-+BUBXL[>?11=3F%4+LP91D%@0I.>N/\:WK;PAIUKX0E\-1R
M7'V.6-XY)2X,K;R2S$XQGGTJQ!X=M+?6+74TDG,]M9?844L-I3(.3QG=P.^/
M:A67]>3_ %8G>W]=U^B9Q%QXKUK2])U2P6XEO+R#6$TZWNC&AEV. P)7A68#
M(&< G&:OV&IZ[I-S<2O::U/I<=G--*=42!625!N&TQGD-R""..*WY/!VE3Q:
MM'/Y\BZG<"YER^#'(  I0@ KC:#WJQI_A_[%,TEQJVIZAF,QA+N92@4]?E55
M!/N<FEK;S_X'^8]+^7_!_P CB-,UCQ5=6>GZK#%KES<W#1R2PO#;K9M$Q&0F
M#O&%/#9R<<]:]/KG++P=!I[11VNK:O%8POOCLEN0(EYSM!"[]O\ L[L5<TC2
M[BQU/5[J:YFDCO+@21122EQ& H!Q_=!.>/856A.IGZOX:U6\\1#6-,UX:?(+
M06VPV:S<;BV<ENYQV[=:QD_M7QIX6@E_T5=7TC5<D'(@N'A8CW(!!]\&NBU7
MPLFIWSW::SK%B\BA)$L[O:C@?[)! /NN*N6>B6FFZ'_9.G&2TA",JR1,#(I/
M5LL#ELG.3GFI6B_K>]RGO_7:QR.EW.I>)OB'%=SV=O:V^AQ212&&<S;YI  4
MW;0. ,D#..._ DU32+#2O'_A9K*V6)KFYNYIG!):1S%U)/)_IVKK-$T:ST#2
MH=.L5811Y)9SEW8\EF/<D\DUDZEX.&IZQ!J<FOZO%-;N[6ZQ&#;#N&"%S$3C
M'J33V:MT%NF7]9GTC1=VOZ@J+-%%Y"2XR[ G.Q1W)..!7GVLZ9=PZ(^JZK#]
MG.LZY:2W5MG(A@#!55_?@9]S78ZWX*AUV_L;V?6=5AFLDVP^1)& &[O@H?G/
MJ,>V*L0^%8#IEYIVI:EJ.K6UVH5UOI$;;C^Z55<'H?P%"TU_K=/\; ]=/ZV:
M_"YG>.@JW7A9TXN!K<"QD==ISO'TV]:/BC_R3O4_K%_Z-2KFF^#++3]1@OY[
M_4M1GME*VWV^X\P0 C!V@ <XXR<FM'Q!H=MXCT2XTJ[DFC@GV[GA(#C#!A@D
M$=1Z4NGSO^*_R&GK_7G_ )E7Q5K,OA_PA>ZG BO-!$/+#=-Q(4$^P)S6'J,F
ML>%ETG4)-<N=16YNXK:[@G2,(WF<;H]J@J0>V3Q6G#X-3$D5]KNLZE:21M')
M:WDT;1NI&.0J \=1SUIUKX,M(;FSEN=1U*_CLF#VL%W,K1Q,!@'A06('0L3B
MJ6]_Z_K^NA/V;&-ITVM>)M-U+6HM=N;!HIYX[2VACC,2",D#S RDL21SR.O%
M5[CQ!K>K:)X>U54U&#3+FW:2^?2HEDF23@#A@3LX8\ GI707'@FREEO/L^H:
ME96UZY>YM;:95BE8_>/*DKGOM(S5NZ\.120VL-CJ.H:7%;1>3&EE*H79V!5E
M8=NN,^]3T^[_ (/WE/?[_P#@$_A^\@O]#M;FVU%]1B=3BY= K/@D<@ 8(Z'@
M=*BT[5-5NM1DM[OP_<65NH;;<O<Q.KX/'RJQ(SUZ5;TC2K71-,AT^S5A#%G!
M=MS,2222>Y))-7:I[DK8X7XC-=)=^%6LHXI+H:LOE)*Y5"VQNI ) _"M26;7
MI?#^L?VU9V%N!:2>5]DG:3/RMG.Y1CM6GJVA6NL7.FSW$DRMI]R+F(1D ,P!
M&&R#QSVQ5V[MDO+.>UD+!)HVC8KU (P<?G4->XUWO^2+3]Y/T_,\BM;R_P!5
M\$^'/"EY90V%CJD$<::C)-O#A<-L50ORNV.,G\ZZ/QIJ5HWB30M"N//:S@87
M]V(;>28X3B)2$4G!;GD=JZ*3PCIDWA.'PY*9GM((U2*4L!*A7[KA@,!AZXJ;
M2?#MOI.H7E^+FZNKN\6-99KEE)VHN !M4 =R?<UHW>5_._\ D9I65O*W^9RG
M@K4H(X_$/A^'SA!:L]S9":%XF,$F3@*X!PK9'2L7PQ'+X.\-:-XFM%=]*N[:
M-=6MU&=AZ"=1[=&]1S7H]YX>M+W7(-7:2>.YBMY+8^6P"R1OV8$'.#R,8YJ;
M2M&M=)T*WT>+?-:P1>2/.PQ9?]K  /Y5*TUZV7X7_-6*>NGK^-OUN>5WT\<_
M@;59%D#:=/XH;[2Z'Y3 902<^AXKV&-(UB5(U41A0%"C@#MCVK$TGP=H^CZ%
M=:+# TNGW,CR/#,0P&[&5' X&.._O5!/A_9I"+7^V]=;3QP+(WO[K;_=R!OV
M^VZA:*WI^27Z!Y^OYW,8G7!\5-?_ +$33F?[';>9]M9P,8.,;0?UKOK'[8;*
M+[>(!=[?WHMR2F?]G/./K7/WO@F"YUN?5K;6=7T^XGB2*06DL:J5087[R$_K
M6UI.G/I=F;=]0O;\[RWG7CJS\]LJH&/PH6UOZW8/>_\ 6R,C1O\ D>/$W^Y:
M?^@-53XASZLGA75H[6PM9;)K)_-FDNBCIP<X0(0>,?Q"M/3+&Y@\6:]=RQ%;
M>Y6V$3Y'S;58-^616Q<VT%Y:RVUS$DL$JE7C<9# ]012:ND4G:5S"MFEO="D
M@\3V&G6UBT<:_P#'X9%D![-N1,<X]<YK'\2?;(/%GA^34DMSHJ7RI:"V)$JS
ME"$,@/!7K]W';-==J.EV>JZ7-IMY")+29-CQ]./;TQ6)8^"+*TO[6[N=2U74
MFM#FVCOK@2)"<8R  ,G'<YJKWE?S_KYD)6C;R'ZE;7(TN_;PG_9?VN>9S=-*
MQ(9\8;E<X?@#G@>E4?"":+=>&-"DLHXQ=V]K(+-;IP9$/W7/'4;AR0/RJU>^
M!K*ZO;NYM]2U73Q>-NNH;*YV1S-C!)!!P2.I!&:GO/!>DW-CI]M;_:-/;3@1
M:3V<NR2($8(!.<@]\@YJ5M]WZC>YE>%C=1^-M=BUE8?[8D@ADWVQ/DF ;@H4
M'Y@V<YSGVKH]6.DV(76]3\J/[ CE)Y/^68;@X]SP/6H=#\-6>A2W-Q'-=7=Y
M=$>?=W<OF2N!T&<  #T %5_$OA*W\3RV;W.HZA;"T?S(TMG0*7[,0R-DCMZ4
MWLK?UN"W=SA_$=I>W/A7Q-XGN8)+0:FMO%';MPZ6R.!N?T9@22.PKI/B,L4?
M@VW-N%$L5Y:FSV]G\Q0-OX9K8LO#"V\5U!>ZOJ>JV]S$8GAOY$=,'KC:BFJE
MCX$TZSN[2:2^U.]BLFW6EM=W.^* C@%1@$D#IDG%-::=+I_=_7XL3[^OX_U^
M!E?$+2+""TBU2.V47T^HV:23DDL5$@P!GH/88JUX]EU"^;3/#.FRK!)J[N)I
MWSA847<XXP<G..#ZUI^(?"B>(V07&KZE;P(R2+!;F(('0Y#?-&3G/OCCI4MW
MX:AO["U@NK^^DNK1S)!?[U2=&.><JH7H<8VX(ZU*6EGW*>]UV,W0;Z_TKQ"/
M"M^ED\:60N+.:SB:)1&K!2C(6;!&1@@U4\=:R#>6OAUY9[2TNE\R]NTB=L0Y
MQY:%0?F;I[#/K70:3X=MM+O9[YKFZO;^91&]U=N&?8.0HV@*HSS@ 5L4WK:X
MEI>QXT^IV'_"&>.K+2&9!Y[/%&D+J! $B4]0,<9XZUUGCY+>/X8-]F"@1K;F
MTV]F#ILVUTUIH-E:#5%P\R:E,TUPDN"N64*0..F%[YK(M/ &F6MQ:L][J=U:
MVCB2VLKFYWP0L/ND+C)QVR3BA>?E^ ;:KS_$@\%8;7?%\DO_ !]?VH5;/7RP
MB[/PQG%<?I@3_A(M-@./[-7Q3?>4/X-PC!3'_ R^*] U3P?9ZCJ<FHPW^HZ;
M=RH(YY+"?R_.4=-P(()'8C!]Z?+X/T:3P[#H:P/%:PL'B>.0B2.0'/F!^N[)
M)S[TEI9]K?U_74;ZKO?^OZZ&;KH5?B7X3:/B9H[M9,=3'Y8(S[;L5;\6?\?W
MAK_L+)_Z*DJQH_A6TTF_DU![N^U"^>/RA<WTPD=$SG:N  !GVH\16-S>7>A/
M;Q&1;?45FE((^5!&XS^9'YTUI;U_43=[^GZ$'C:]O=*T:'5;.9T2RNHI;E%_
MY:0;L.#^!S^%8B^*KR/QM+<RW 'AQFDL4X&!-'&)"^??YU_X#7;WUG#J-A<6
M5PNZ&XC:*0>JL,&N?F\!:1-X/C\,L]U]DC;>)@X\XMN+%BV,9.2#QT-+7^O/
M1_YCT_K[_P#@&#IFLZS:CPUK.I7LALM6FF2>%P-L0DRT';C 4#\:JVOC75+2
MSUN]OI"R7EJU[HZ%1\JES$J>_)C;_@5=SK?ANPUWP^=&N/-BML($:!@KQ[2"
MI4D''3TJOJ/@_2M3;1S,LB+I+JUNL;  @8PK<<KE5...@IV6W3]/\]/Q%=[]
M?U_RU_ YXZWJ7A/4)8=8O9+J-]&%S$9,<W$0Q(HQ_>W*:HV^OZ^FA#0+R\8>
M(GU&&U\]0-PCD E+@=.$WC\*[77O#&G^(Y-/DOO-S8SB>/RV W$?PMD'*G R
M/:B7PQI\WBN#Q&WF_;88#"JAAL(Y^8C&=P!(SGH::>MW_77_ ('H*VFG]/;_
M (/J0^,]0OM*\*7=YI[[)H]FZ7:&,:%@&8 \$@9('K7*P:UJ5G<ZC?V6JZIJ
M6BV&G/<-]MM5CWS@'";C&K$8Y..GZ5K^)O#=R=!U"&R:]OQ?7J7%S#)."Z1A
M@66 G 4C (!/]*K:18:C<:Y"(TUQ-&\F1+V+69ED$N1A5122W7J>!CUJ=7?^
MNG]?,K16_KK_ %\BAI6I^*9/[+ODBUVYEN'C:Z2XAMUM3&WWBFT[EP#D'G..
M>M3VS:WJY\4S#Q#>6J:=>S1VL<*1X&U PW%E)8<].._X=#8>$8M->!(-8U?[
M';L&BLS<CRU Z+D*'*CT+$5<LO#UI8QZLD4DY&ISO/-N8?*SJ%(7C@8'?-.6
MJ?+YV_04=U?R_6YP%TUSXDU'P!J4VH7=M-?12EQ;LJA&$1)9<J<$]#UXK3NY
M[ZZ?QQILFI70AL;2'R&!7</W)9N<?Q$<_IBNBM?"&GVBZ"L<UR1HBLMMN9?G
M#+M._P"7GCTQ5F/PY9)?ZQ=L97;5D1+A&8;0%0I\N!D9!]31-732\_QM;]0A
MHTWY?A>YG^ K%K3PAIDC7MU<":TA8).RE8OD'"X P.>^>E4;!]4\4ZKK4BZU
M=:=;:?>-9V\-JL?+* 2[EU;=DGIP,5H6W@V&VTRWT]=9U@P6\L<D7^D*I4)T
M3*J,KZ@\G YJ2Y\(VTNI7-]::CJ6G27>#<I9S*JS$#&X@J<-CC*X-5)WDV**
MM&QG&;4M<\6ZAHRZM<V-KI<$)=[94$D\D@)W$LI 4 = .M8EUXDUP:0UF-0V
MWUIX@BTUKQ8E_>QL1@LO3.&Y QTKK[SPI;7-['?6U]?V%XL(@>XMI1NE0= ^
M\,&(]2,^]1_\(7I8TRVL$:Y5(+U+\R^8#)-,K;MSL0<Y/7I[8J5Y_P!:_P"7
M^0WY?UI_F8L<6LOXRN?#9\1W_P!D%FMZ)]D7GABQ79NV8VY&?NY[9Q6SX'U6
M\U?PS'/?R"6YBFE@>4*%\S8Y4-@< D 5HKHMLGB.37 \OVJ2U%J4R-FP,6SC
M&<Y/K1H>B6V@:>UG:O*\;323$RD$Y=BQZ <9-"VU_K7_ "!^7]:?YFE1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
